EBV-specific Cytotoxic T-lymphocytes (CTLs) for Refractory EBV Infection
Status:
Recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
Related donor Epstein-Barr Virus (EBV) specific cytotoxic T cells (CTLs) manufactured with
the Miltenyi CliniMACS Prodigy Cytokine Capture System will be administered in children,
adolescents and young adults with refractory EBV infection post Allogeneic Hematopoietic Stem
Cell Transplantation (AlloHSCT), with primary immunodeficiencies (PID) or post solid organ
transplant.
Funding Source: FDA OOPD
Phase:
Phase 2
Details
Lead Sponsor:
New York Medical College
Collaborators:
Children's Hospital of Philadelphia Medical College of Wisconsin